Top Six Trials From AHA 2024: BROAD, SUMMIT, OPTION, CLEAR SYNERGY (Spironolactone and Colchicine), My Heart Your Heart
In this special edition of Eagle’s Eye View, Dr. Eagle looks at the most important trials presented at the recent AHA scientific sessions: 1) BROAD, exploring more intensive blood pressure control; 2) SUMMIT, evaluating tirzepatide use in obesity-related HFpEF in people with diabetes; 3) OPTION, comparing left atrial appendage closure to oral anticoagulation therapy for stroke protection in post-ablation patients with atrial fibrillation; 4) CLEAR SYNERGY, dual trials on the use of spironolactone vs. placebo and colchicine vs. placebo in patients with myocardial infarction, and 5) Project My Heart Your Heart, developing a protocol of the use of refurbished pacemakers.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Anticoagulation Management, Heart Failure and Cardiomyopathies, Prevention, Acute Heart Failure, Hypertension, Arrhythmias and Clinical EP
Keywords: Anticoagulants, Atrial Appendage, Diabetes Mellitus, Type 2, Hypertension, Heart Failure, Glucagon-Like Peptide-1 Receptor, Mineralocorticoid Receptor Antagonists, Myocardial Infarction, Pacemaker, Artificial, AHA24, EaglesEyeView